Robert Hershberg Adaptive Biotechnologies Corp (ADPT) insider trading activity

Robert Hershberg is Director of Adaptive Biotechnologies Corp. Currently has a direct ownership of 46,722 shares of ADPT, which is worth approximately $658,780. The most recent transaction as insider was on Dec 10, 2025, when has been sold 22,968 shares (Common Stock) at a price of $16.0 per share, resulting in proceeds of $367,488. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 46.7K

32.96% 3M change

56.46% 12M change

Total Value Held $658,780

ROBERT HERSHBERG Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Dec 10 2025	SELL Open market or private sale	$367,488 $16.0 p/Share	22,968 Reduced 32.96%	46,722 Common Stock
Mar 12 2025	SELL Open market or private sale	$402,270 $7.59 p/Share	53,000 Reduced 43.2%	69,690 Common Stock
Mar 04 2025	BUY Grant, award, or other acquisition	-	15,394 Added 11.15%	122,690 Common Stock
Mar 04 2024	BUY Grant, award, or other acquisition	-	31,328 Added 22.6%	107,296 Common Stock
Mar 06 2023	BUY Grant, award, or other acquisition	-	14,775 Added 16.28%	75,968 Common Stock
Feb 02 2023	BUY Exercise of conversion of derivative security	$23,850 $0.45 p/Share	53,000 Added 46.41%	61,193 Common Stock
Jan 26 2022	BUY Grant, award, or other acquisition	-	6,689 Added 44.95%	8,193 Common Stock

Mar 08 2021	SELL Open market or private sale	$89,120 $44.56 p/Share	2,000 Reduced 57.08%	1,504 Common Stock
Mar 08 2021	SELL Open market or private sale	$89,120 $44.56 p/Share	2,000 Reduced 100.0%	0 Common Stock
Mar 08 2021	BUY Exercise of conversion of derivative security	$900 $0.45 p/Share	2,000 Added 36.34%	3,504 Common Stock
Mar 08 2021	BUY Exercise of conversion of derivative security	$900 $0.45 p/Share	2,000 Added 50.0%	2,000 Common Stock
Feb 16 2021	SELL Open market or private sale	$130,900 $65.45 p/Share	2,000 Reduced 57.08%	1,504 Common Stock
Feb 16 2021	BUY Exercise of conversion of derivative security	$900 $0.45 p/Share	2,000 Added 36.34%	3,504 Common Stock
Feb 14 2021	BUY Grant, award, or other acquisition	-	1,504 Added 50.0%	1,504 Common Stock
Jan 15 2021	SELL Open market or private sale	$133,400 $66.7 p/Share	2,000 Reduced 100.0%	0 Common Stock
Jan 15 2021	BUY Exercise of conversion of derivative security	$900 $0.45 p/Share	2,000 Added 50.0%	2,000 Common Stock
Dec 15 2020	SELL Open market or private sale	$112,780 $56.39 p/Share	2,000 Reduced 100.0%	0 Common Stock
Dec 15 2020	BUY Exercise of conversion of derivative security	$900 $0.45 p/Share	2,000 Added 50.0%	2,000 Common Stock
Nov 16 2020	SELL Open market or private sale	$96,000 $48.0 p/Share	2,000 Reduced 100.0%	0 Common Stock
Nov 16 2020	BUY Exercise of conversion of derivative security	$900 $0.45 p/Share	2,000 Added 50.0%	2,000 Common Stock
Oct 15 2020	SELL Open market or private sale	$103,020 $51.51 p/Share	2,000 Reduced 100.0%	0 Common Stock
Oct 15 2020	BUY Exercise of conversion of derivative security	$900 $0.45 p/Share	2,000 Added 50.0%	2,000 Common Stock

Also insider at

NSTG

NanoString Technologies Inc Healthcare

Director

SBTX

Silverback Therapeutics, Inc. Healthcare

Director

RXRX

RECURSION PHARMACEUTICALS, INC. Healthcare

Director

FATE

FATE THERAPEUTICS INC Healthcare

Director

HLVX

HilleVax, Inc. Healthcare

President and CEO

ATAI

ATAI Life Sciences N.V. Healthcare